SANA — Sana Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $1.06bn
- $909.75m
- 32
- 11
- 58
- 24
Annual income statement for Sana Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 286 | 357 | 273 | 293 | 273 |
| Operating Profit | -286 | -357 | -273 | -293 | -273 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -285 | -356 | -269 | -283 | -267 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -285 | -356 | -269 | -283 | -267 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -285 | -356 | -269 | -283 | -267 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -285 | -356 | -269 | -283 | -267 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.55 | -2.14 | -1.43 | -1.46 | -1.15 |